Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2016-07-22 Regulatory Filings
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is explicitly titled "PRESS RELEASE" and details a positive opinion received from the CHMP (Committee for Medicinal Products for Human Use) of the EMA regarding the marketing authorization for the drug Cabometyx™. It includes key efficacy data (OS, PFS, ORR) from the METEOR Phase 3 trial and discusses regulatory steps (EC review). This content structure—a formal announcement of a significant regulatory/clinical milestone for a pharmaceutical product—is characteristic of a general press release related to corporate or product news, rather than a comprehensive financial report (10-K, IR) or a specific regulatory filing like a Director's Dealing or Dividend Notice. Since there is no specific category for a 'Pharmaceutical Regulatory Milestone Announcement,' and it is not a report itself but an announcement of a regulatory step, the most appropriate fallback category is 'Regulatory Filings' (RNS), as it is a general regulatory announcement that doesn't fit the other specific financial/corporate action codes.
2016-07-22 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding the marketing authorization recommendation for Cabometyx™ in the EU. It details clinical trial results (METEOR study) and provides background on the drug and the companies involved (Ipsen and Exelixis). This format—a formal announcement of a significant regulatory/clinical milestone via a press release—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific announcement about a regulatory decision (CHMP opinion) and not a comprehensive financial report (like 10-K or IR) or a transcript, it fits best as an Earnings Release (ER) if it were tied to a reporting period, or more generally, a Regulatory Filing (RNS). Given the content focuses heavily on clinical/regulatory news rather than quarterly financial performance highlights, and it is a formal announcement, it leans towards a general regulatory announcement or press release. However, in the context of financial filings, major drug approvals/opinions are often disseminated via press releases that function similarly to an Earnings Release (ER) announcing key operational news, or as a general Regulatory Filing (RNS). Since the document is a detailed press release announcing a major regulatory step (CHMP positive opinion) and includes extensive clinical data, it is a significant corporate announcement. If it were purely a regulatory filing without the press release structure, RNS would be appropriate. Given the structure and the nature of the news (regulatory milestone), ER (Earnings Release, often used broadly for major operational news releases) or RNS (Regulatory Filings) are the closest fits. I will select ER as these types of announcements often accompany or substitute for formal earnings reporting when major operational news is released, though RNS is also plausible. Given the focus on a specific regulatory event, RNS is the most neutral and accurate fit for a non-standard report announcement.
2016-07-22 French
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Earnings Release Classification · 99% confidence The document is a press release dated July 18, 2016, announcing that Ipsen's application for marketing authorization for telotristat etiprate has been accepted by the European Medicines Agency (EMA). It details regulatory submissions in Europe (EMA, SwissMedic) and the US (FDA), summarizes Phase 3 clinical trial results (TELESTAR, TELECAST), and provides background information on the condition (carcinoid syndrome) and the drug. This content structure—a formal announcement of a significant regulatory/clinical milestone, often including trial data summaries and management commentary—is characteristic of a major corporate news release, typically classified as an Earnings Release (ER) if it were tied to financial periods, or more generally as a Regulatory Filing (RNS) if it concerns regulatory progress. However, since it is a detailed announcement about regulatory progress and clinical data, and not a standard quarterly earnings report (ER) or a general regulatory filing (RNS), it best fits the category of a significant corporate announcement. Given the options, and since it is not a full financial report (10-K, IR) or a presentation (IP), it functions as a major corporate update. In many databases, such detailed, non-financial-period-specific announcements about regulatory progress are often grouped under a general regulatory or news category. Since 'RNS' is the fallback for miscellaneous filings, and this is a specific regulatory update that doesn't fit the other specific categories (like DIV, CAP, MANG), RNS is the most appropriate general classification for a significant, non-financial-period-specific regulatory announcement that isn't a full report. FY 2016
2016-07-18 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 95% confidence The document is a press release dated July 18, 2016, announcing that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for a drug (telotristat etiprate). It details regulatory submissions in Europe (EMA, SwissMedic) and the US (FDA), clinical trial results (TELESTAR, TELECAST), and provides company background. This type of announcement, focusing on regulatory milestones and clinical data updates outside of routine financial reporting periods (like 10-K or IR), is best classified as a general regulatory announcement or press release concerning product development and regulatory progress. Since it is not a formal financial report (10-K, IR, ER, MRQ) nor a specific legal/governance filing, and it is a direct announcement of a regulatory event, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for non-standard regulatory news releases.
2016-07-18 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Board/Management Information Classification · 99% confidence The document is a press release dated July 11, 2016, announcing the appointment of David Meek as the new Chief Executive Officer (Directeur général) of Groupe Ipsen, effective July 18, 2016, and detailing the transition of the former CEO, Marc de Garidel. This content directly relates to changes in senior management personnel. Based on the provided definitions, this clearly falls under 'Board/Management Information' (Code: MANG). The document is not a financial report (10-K, IR, ER), a shareholder vote result (DVA), or a general regulatory filing (RNS), but a specific announcement about executive leadership.
2016-07-11 French
Communicated under the obligation to provide permanent information / Other communications
Board/Management Information Classification · 99% confidence The document text is a press release announcing a significant change in senior management: the appointment of David Meek as Chief Executive Officer and the transition of Marc de Garidel to non-executive chairman. This content directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management. It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2016-07-11 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.